Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > ORGANIZATION
ORGANIZATION
- Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
September 5, 2022
- FPMAJ Chief Advocates Drug Price Revision Rule Based on Appropriate Margins for Each Player
September 2, 2022
- JPMA Proposes New Value-Based Pricing System for Innovative Meds, No Price Cut in Patent Period
August 31, 2022
- JPMA Urges Govt to Expand Support to Boost Competitiveness of Japan Pharma Industry
August 31, 2022
- Allocate All Savings from Off-Year Drug Re-Pricing to Medical Fees: Hodanren
August 31, 2022
- JaDHA Hopes to Issue First Policy Proposal to Solve Digital Health Challenges by Year-End: Chairman
August 17, 2022
- Single-Wholesaler Distribution Should Be Redressed from Stable Supply Standpoint: JMA Official
August 4, 2022
- JPWA Chief Questions Patient Benefits of Single-Wholesaler Distribution
August 1, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
- JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
- JPMA Hails New Expert Panel, Plans to Raise “Drug Loss” Issue: Director General
July 25, 2022
- Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
- FPMAJ Lauds Ruling Bloc Election Win, Urges Drastic Social Security Debate
July 12, 2022
- FPMAJ Chief Thanks Abe for AMED Launch, Vows to Carry On Innovative Drug Discovery
July 12, 2022
- Regenerative Medicine Makers Have “Good Reasons” to Opt for Single-Wholesaler Route: FIRM Chair
July 12, 2022
- JPMA Think Tank Finds Surge in Japan-Unapproved Drugs in Areas with High Unmet Needs
July 12, 2022
- JPMA Committed to Building Drug Discovery Ecosystem: President
July 5, 2022
- INES Launches Study Group to Propose Stable Healthcare Financing
July 4, 2022
- Generic Use Rate Stands at 79.5% in FY2021: JGA
June 30, 2022
- Kichiro Matsumoto Elected as New Chief of Japan Medical Association
June 27, 2022
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…